Logo image of SPRO

SPERO THERAPEUTICS INC (SPRO) Stock Fundamental Analysis

NASDAQ:SPRO - Nasdaq - US84833T1034 - Common Stock - Currency: USD

0.578  -0.01 (-2.03%)

Fundamental Rating

3

SPRO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 563 industry peers in the Biotechnology industry. The financial health of SPRO is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SPRO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SPRO had negative earnings in the past year.
SPRO had a negative operating cash flow in the past year.
SPRO had negative earnings in 4 of the past 5 years.
SPRO had a negative operating cash flow in each of the past 5 years.
SPRO Yearly Net Income VS EBIT VS OCF VS FCFSPRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -62.03%, SPRO is doing worse than 60.92% of the companies in the same industry.
SPRO has a Return On Equity of -148.66%. This is in the lower half of the industry: SPRO underperforms 63.23% of its industry peers.
Industry RankSector Rank
ROA -62.03%
ROE -148.66%
ROIC N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
SPRO Yearly ROA, ROE, ROICSPRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRO Yearly Profit, Operating, Gross MarginsSPRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

5

2. Health

2.1 Basic Checks

SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SPRO has more shares outstanding
Compared to 5 years ago, SPRO has more shares outstanding
There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SPRO Yearly Shares OutstandingSPRO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SPRO Yearly Total Debt VS Total AssetsSPRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -6.61, we must say that SPRO is in the distress zone and has some risk of bankruptcy.
SPRO's Altman-Z score of -6.61 is on the low side compared to the rest of the industry. SPRO is outperformed by 65.90% of its industry peers.
SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.61
ROIC/WACCN/A
WACC10.07%
SPRO Yearly LT Debt VS Equity VS FCFSPRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.19 indicates that SPRO has no problem at all paying its short term obligations.
SPRO's Current ratio of 2.19 is on the low side compared to the rest of the industry. SPRO is outperformed by 74.07% of its industry peers.
A Quick Ratio of 2.19 indicates that SPRO has no problem at all paying its short term obligations.
With a Quick ratio value of 2.19, SPRO is not doing good in the industry: 72.65% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 2.19
SPRO Yearly Current Assets VS Current LiabilitesSPRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SPRO have decreased strongly by -344.23% in the last year.
Looking at the last year, SPRO shows a very negative growth in Revenue. The Revenue has decreased by -53.77% in the last year.
Measured over the past years, SPRO shows a very strong growth in Revenue. The Revenue has been growing by 21.46% on average per year.
EPS 1Y (TTM)-344.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.58%
Revenue 1Y (TTM)-53.77%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-79.54%

3.2 Future

SPRO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.25% yearly.
SPRO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.51% yearly.
EPS Next Y0.01%
EPS Next 2Y37.68%
EPS Next 3Y-12.65%
EPS Next 5Y20.25%
Revenue Next Year-100%
Revenue Next 2Y-81.73%
Revenue Next 3Y-5.87%
Revenue Next 5Y19.51%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SPRO Yearly Revenue VS EstimatesSPRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 0 50M 100M 150M 200M
SPRO Yearly EPS VS EstimatesSPRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SPRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SPRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRO Price Earnings VS Forward Price EarningsSPRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRO Per share dataSPRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A cheap valuation may be justified as SPRO's earnings are expected to decrease with -12.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.68%
EPS Next 3Y-12.65%

More info and screens

0

5. Dividend

5.1 Amount

SPRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPERO THERAPEUTICS INC

NASDAQ:SPRO (5/7/2025, 4:30:02 PM)

0.578

-0.01 (-2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-09 2025-05-09/amc
Inst Owners25.51%
Inst Owner Change-0.17%
Ins Owners5.2%
Ins Owner Change16.42%
Market Cap32.32M
Analysts77.78
Price Target5.1 (782.35%)
Short Float %1.93%
Short Ratio5.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.26%
Min EPS beat(2)-20.18%
Max EPS beat(2)13.65%
EPS beat(4)2
Avg EPS beat(4)-108.67%
Min EPS beat(4)-443.03%
Max EPS beat(4)14.86%
EPS beat(8)6
Avg EPS beat(8)112.25%
EPS beat(12)8
Avg EPS beat(12)169.15%
EPS beat(16)9
Avg EPS beat(16)126.61%
Revenue beat(2)2
Avg Revenue beat(2)105.06%
Min Revenue beat(2)72.24%
Max Revenue beat(2)137.89%
Revenue beat(4)3
Avg Revenue beat(4)89.59%
Min Revenue beat(4)-57.81%
Max Revenue beat(4)206.03%
Revenue beat(8)7
Avg Revenue beat(8)120.31%
Revenue beat(12)9
Avg Revenue beat(12)87.58%
Revenue beat(16)11
Avg Revenue beat(16)69.4%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-107.55%
EPS NQ rev (3m)-107.55%
EPS NY rev (1m)-119.7%
EPS NY rev (3m)-119.7%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.67
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.86
BVpS0.82
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.03%
ROE -148.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 2.19
Altman-Z -6.61
F-Score2
WACC10.07%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-344.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.58%
EPS Next Y0.01%
EPS Next 2Y37.68%
EPS Next 3Y-12.65%
EPS Next 5Y20.25%
Revenue 1Y (TTM)-53.77%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-79.54%
Revenue Next Year-100%
Revenue Next 2Y-81.73%
Revenue Next 3Y-5.87%
Revenue Next 5Y19.51%
EBIT growth 1Y-370.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y28.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.95%
OCF growth 3YN/A
OCF growth 5YN/A